Drug use among youth : findings from the 1988 National Household Survey on Drug Abuse.

Mode of access: Internet.

Prevalence of drug use in the Washington, DC, Metropolitan Area homeless and transient population, 1991.

Shipping list no.: 93-0546-P.

Self-report methods of estimating drug use : meeting current challenges to validity /

S/N 017-024-02146-7

A study of legal drug use by older Americans.

Mode of access: Internet.

Illicit drug use and return to treatment : national followup study of admissions to drug abuse treatments in the DARP during 1969-1971 /

Mode of access: Internet.

Drug use in industry /

Mode of access: Internet.

Monitoring drug use in the community through a jail urine screening program /

Mode of access: Internet.

Prevalence of drug use in the DC Metropolitan Area institutionalized population, 1991.

Shipping list no.: 94-0324-P.

The aging process and psychoactive drug use.

Produced under NIDA contract no. 271-75-1140, Work Order no. 9.

Alcohol, tobacco, and other drug use by women in the Illinois child welfare system : prevalence - treatment need - impact on children.

"This report represents a joint effort between the Illinois Department of Alcoholism and Substance Abuse (DASA) and Department of Children and Family Services (DCFS). The study examined alcohol, tobaccco, and other drug abuse (ATODA) and need for treatment among adults involved with the child welfare system in Illinois. The purpose of the study was to provide data on the relationships between ATODA and child abuse and neglect"--P. iii.

Results of the 1995 Illinois Drug Use forecasting study /

"July 1996."

The incidence and prevalence of drug use among adults in Illinois /

Research conducted by the Institute for Juvenile Research from a grant (C7-0069-01) of the Illinois Dangerous Drugs Commission.

Audit of selective and non-selective non-steroidal anti-inflammatory drug use in rural general practice

Aim: To identify the demographics and risk factors in a selected patient population prescribed non-selective and cyclo-oxygenase-2 (COX- 2) selective non-steroidal anti-inflammatory drugs (NSAIDs). Method: A structured clinical self-audit form was distributed in January to March 2001 to 155 interested general practitioners (GPs) in rural Queensland. Results: Seventy one GPs participated in the audit and contributed 1417 patient records - 790 patients had received nonselective NSAIDs and 627 had received COX-2 inhibitors (celecoxib or rofecoxib). Patients who received COX-2 inhibitors were significantly older, more likely to have clinically important concomitant illness, and more likely to be taking medication known to interact with NSAIDs. They were also twice as likely to have two or more risk factors for adverse effects. The most common reasons for switching from an NSAID to a COX-2 inhibitor were reported to be a previous side effect from an NSAID (primarily related to gastrointestinal effects) or the doctor's perception of the superior efficacy of COX-2 inhibitor therapy. Conclusions: This study has shown that COX-2 inhibitors were used in a distinctly different patient population compared to non-selective NSAIDs. There were significant variations in the demographics and number of risk factors - for example, cardiovascular and renal - between the two identified populations. These differences may be due to doctors selecting COX-2 inhibitors for patients at high risk of gastrointestinal complications. However, the prescribing pattern may also be partly due to misconceptions about the relative safety and efficacy of COX-2 inhibitor drugs.

Effects of reduction in heroin supply on injecting drug use: analysis of data from needle and syringe programmes

n early 2001 there was a dramatic decline in the availability of heroin in New South Wales (NSW), Australia, where previously heroin had been readily available at a low price and high purity.1 The decline was confirmed by Australia's strategic early warning system, which revealed a reduction in heroin supply across Australia and a considerable increase in price,2 particularly from January to April 2001. This "heroin shortage" provided a natural experiment in which to examine the effect of substantial changes in price and availability on injecting drug use and its associated harms in Australia's largest heroin market,2 a setting in which harm reduction strategies were widely used. Publicly funded needle and syringe programmes were introduced to Australia in 1987, and methadone maintenance programmes, which were established in the 1970s, were significantly expanded in 1985 and again in 1999.